Article3 Biotech2025
Deciphering the prognostic signature of nonsmall cell lung cancer using cisplatin resistance and circulating tumor cell-related gene analysis.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop a prognostic prediction model for nonsmall cell lung cancer (NSCLC) based on cisplatin resistance and circulating tumor cell (CTC)-related genes and to explore the molecular mechanisms of key genes. After downloading and preprocessing data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases, a prognostic signature was developed using least absolute shrinkage and selection operator (LASSO) regression analysis. Patients were categorized into low-risk (LR) and high-risk (HR) groups based on their risk score (RS), and differences in survival, immune infiltration, and immunotherapy/chemotherapy responses were compared. A nomogram was established for clinical application, followed by identification of molecular subtypes. Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to verify the expression of key genes in the A549 and A549/DDP cell lines. Finally, we explored the molecular mechanisms by which inhibition of FAM83A reversed cisplatin resistance. Using LASSO regression, a prognostic signature with eight genes was developed; the survival rate of patients in the HR group was significantly lower than that of patients in the LR group (all
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.